- Home
- SNPX vs CTHR Comparison
SNPX vs CTHR Comparison
Compare SNPX & CTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNPX
- CTHR
- Stock Information
- Founded
- SNPX 2012
- CTHR 1995
- Country
- SNPX United States
- CTHR United States
- Employees
- SNPX N/A
- CTHR N/A
- Industry
- SNPX Medicinal Chemicals and Botanical Products
- CTHR Consumer Specialties
- Sector
- SNPX Health Care
- CTHR Consumer Discretionary
- Exchange
- SNPX Nasdaq
- CTHR Nasdaq
- Market Cap
- SNPX 3.8M
- CTHR 5.8M
- IPO Year
- SNPX N/A
- CTHR 1997
- Fundamental
- Price
- SNPX $3.01
- CTHR $1.73
- Analyst Decision
- SNPX Strong Buy
- CTHR
- Analyst Count
- SNPX 1
- CTHR 0
- Target Price
- SNPX $14.00
- CTHR N/A
- AVG Volume (30 Days)
- SNPX 39.8K
- CTHR 8.2K
- Earning Date
- SNPX 08-14-2024
- CTHR 11-07-2024
- Dividend Yield
- SNPX N/A
- CTHR N/A
- EPS Growth
- SNPX N/A
- CTHR N/A
- EPS
- SNPX N/A
- CTHR N/A
- Revenue
- SNPX N/A
- CTHR $23,684,860.00
- Revenue This Year
- SNPX N/A
- CTHR $31.82
- Revenue Next Year
- SNPX N/A
- CTHR N/A
- P/E Ratio
- SNPX N/A
- CTHR N/A
- Revenue Growth
- SNPX N/A
- CTHR N/A
- 52 Week Low
- SNPX $2.72
- CTHR $1.51
- 52 Week High
- SNPX $11.48
- CTHR $8.00
- Technical
- Relative Strength Index (RSI)
- SNPX 40.82
- CTHR 60.36
- Support Level
- SNPX $2.72
- CTHR $1.57
- Resistance Level
- SNPX $3.67
- CTHR $1.87
- Average True Range (ATR)
- SNPX 0.28
- CTHR 0.08
- MACD
- SNPX -0.04
- CTHR 0.04
- Stochastic Oscillator
- SNPX 33.58
- CTHR 100.00
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
About CTHR Charles & Colvard Ltd
Charles & Colvard Ltd manufactures, markets, and distributes finished jewellery which also includes moissanite gemstone in the jewellery market. The company sells jewels through two operating segments namely Online Channels segment and Traditional segment. It generates maximum revenue from the Online Channels segment. Online Channels segment which consists of e-commerce outlets including charlesandcolvard.com, moissaniteoutlet.com, third-party online marketplaces, drop-ship retail, and other pure-play, exclusively e-commerce outlets.